Home › Blood Disorders › California › Orange
Blood Disorders clinical trials in Orange, CA
3 studies for Blood Disorders are looking for participants at sites in and around Orange (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RecruitingPhase 3
- Ctr for Inherited Blood Disorders, Orange
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RecruitingPhase 3
- UCI Health - UCI Medical Center, Orange
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
About Blood Disorders
Blood disorders affect one or more parts of the blood and prevent your blood from doing its job. Find out about the types, causes, and treatments.
More about Blood Disorders on MedlinePlus
Blood Disorders trials in other cities
- Houston, TX11 studies
- Atlanta, GA11 studies
- Boston, MA10 studies
- Los Angeles, CA10 studies
- New York City, NY9 studies
- The Bronx, NY8 studies
- Durham, NC7 studies
- Nashville, TN7 studies
- Mountain View, CA7 studies
- San Diego, CA6 studies
- Seattle, WA6 studies
- Indianapolis, IN5 studies
Other studies in Orange
- Non-Small Cell Lung Cancer28 studies
- Metastatic Cancer21 studies
- Ovarian Cancer16 studies
- Colorectal Cancer16 studies
- Cancer (all types)15 studies
- Pancreatic Cancer15 studies
- Lung Cancer15 studies
- Liver Cancer (Hepatocellular Carcinoma)14 studies
- Melanoma14 studies
- Major Depressive Disorder13 studies
- Stomach Cancer13 studies
- Prostate Cancer13 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.